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F proteinA comprehensive analysis of sequence variation was carried out comparing the fusion (F) protein of
human respiratory syncytial viruses (hRSV) from antigenic groups A and B with the prototype sequence
of the A2 strain, also belonging to antigenic group A. The limited number of full bovine RSV F sequences
available were included, as well as an extensive set of F sequences from the related human metapneu-
movirus (hMPV). The results were analysed in the context of the recently determined three dimensional
F protein structures, with antigenic sites mapped to these. Although a high degree of sequence conserva-
tion in hRSV F exists, and sequence changes did not correlate with location of antigenic sites, preferential
accumulation of amino acid changes in certain antigenic sites was noted. When the analysis was
extended to hMPV F, a high number of changes was noticed, in agreement with the limited degree of
sequence conservation. However, some conserved regions were noted, which may account for the limited
number of cross-reactive monoclonal antibodies described between hRSV F and hMPV F. These results
provide information about the degree of sequence and antigenic variation currently found in the F protein
of circulating viruses. They highlight the importance of establishing a baseline dataset to monitor for
future changes that might evolve should preventative immunological measures be made widely
available.
 2018 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Human Respiratory Syncytial Virus (hRSV) is an enveloped virus
of the Orthopneumovirus genus within the newly created Pneu-
moviridae family [1] which also includes bovine RSV (bRSV) and
pneumonia virus of mice (PVM). hRSV strains are classified into
two main antigenic groups - hRSV A and hRSV B- which cause sea-
sonal epidemics in winter months and circulate worldwide. For
each group a number of clades have been identified (currently 16
for hRSV A and 22 for hRSV B) [2]. hRSV has a negative stranded
RNA genome which is approximately 15 kb long with 10 gene tran-
scripts encoding 11 proteins [3], two of them being the major sur-
face glycoproteins, namely the attachment or G glycoprotein and
the fusion (F) glycoprotein.In 2015, it was estimated that infection with hRSV resulted in
33.1 million episodes of lower respiratory infection (bronchiolitis
and pneumonia) leading to 3.2 million hospitalisations and
around 120,000 deaths worldwide in children younger than five
years [4]. In addition, hRSV is an important cause of respiratory
disease in the elderly and in immunocompromised adults, con-
tributing to a substantial disease burden in these populations
[5]. Despite such a high disease burden, no licensed hRSV vaccine
is yet available. Initial attempts to create an hRSV vaccine in the
1960s were unsuccessful: a heat and formalin inactivated whole
virus vaccine administered to young children did not only fail
to prevent infection in the subsequent season, but led to more
severe infection (enhanced disease) upon natural infection in a
high percent of vaccinees and two deaths [6]. However, almost
twenty prophylactic vaccine candidates and monoclonal antibod-
ies (mAbs) are now in clinical trials, progressing from Phase I to
III [7]. If, when available, they achieve widespread use, these vac-
cines could have a substantial effect on hRSV disease morbidity
and mortality.ared to
2 V. Mas et al. / Vaccine xxx (2018) xxx–xxxThis new impetus in the search for a much needed hRSV vaccine
originates mainly from the realisation that protection against virus
infection correlates with high levels of neutralising antibodies [8,9]
which are mostly directed against one of the hRSV glycoproteins:
the F glycoprotein. This glycoprotein mediates fusion of the viral
and cell membranes, allowing entry of the viral ribonucleoprotein
into the cell cytoplasm and thus initiation of a new infectious cycle
[10].
The primary structure of the F glycoprotein consists of two seg-
ments, F1 and F2, produced by the cleavage of the precursor (F0) at
Arg109 and Arg136, with the release of the intervening 27 amino
acid fragment (p27). The F protein is incorporated into virus parti-
cles in a metastable conformation called prefusion, the 3-D struc-
ture of which was recently determined [11]. During membrane
fusion, the F protein refolds into a highly stable conformation,
denoted postfusion, the structure of which is also known [12]
and which shares only some epitopes with the prefusion confor-
mation. So far, six antigenic sites (Ø and I-V) have been identified
in prefusion F, three of which are also represented in postfusion F.
It has become clear in recent years that the most potent human
neutralising antibodies recognise epitopes specific to the prefusion
form of hRSV F [13]. Hence, most current vaccines under develop-
ment, some of them already in clinical trials, rely on induction of
antibody responses to epitopes of the F glycoprotein, particularly
those specific to its prefusion conformation. Similarly, although
palivizumab, a mAb licensed for prophylactic prevention of hRSV
infections, recognises an epitope of antigenic site II shared by pre-
fusion and postfusion hRSV F, other mAbs under development,
such as MEDI8897, target epitopes of antigenic site Ø, specific to
the prefusion F [14]. The F protein is also being considered as a tar-
get of small molecules under development as therapeutic agents
[15].
The F glycoprotein is known to have a high level of sequence
conservation among hRSV strains [16]. This level of sequence iden-
tity is also reflected in a high level of antigenic conservation. John-
son et al. [17] reported that immunisation of cotton rats with a
vaccinia virus recombinant expressing the F protein from a group
A virus induced cross-protective immunity not only to group A,
but also group B, viruses. However, whilst the F protein may be suf-
ficient to stimulate a cross-protective immune response between
hRSV antigenic groups, there are potential scenarios in which
immune selective pressures on hRSV F might act to increase F pro-
tein variation, with a possible impact on their effectiveness. The
first is if a neutralising mAb targeting a specific F protein epitope
were to be used so widely as to impose a strong selective pressure
on hRSV F. This in turn might lead to selection for escape mutants
with sequence changes in the targeted epitope. A precedent for
generation of escape mutants exists both in vitro and in clinical
settings. In a laboratory setting, prolonged treatment of hRSV with
mAbs has been shown to select for mutants with reduced antibody
binding affinities for antibodies binding to antigenic sites II, III, IV
and Ø [18–24]. Clinically, cohorts of patients treated prophylacti-
cally with palivizumab or the related mAbmotavizumab have been
found to be infected with hRSV strains with mAb resistance-
associate mutations [25,26].
The second scenario is if an hRSV vaccine inducing F specific
antibodies were to be widely used as part of vaccination cam-
paigns. In this case, there might be a selective advantage for hRSV
mutants with amino acid changes in the relevant epitopes of the F
protein incorporated into the vaccine.
We therefore set out to investigate variability of F protein
sequences in a comprehensive dataset of hRSV and bRSV strains
and the highly related (particularly at the F structural level) human
metapneumovirus (hMPV). The rationale for this approach was to
identify regions of the F protein sequence which are either more
conserved or more variable in the context of the prefusion hRSVPlease cite this article in press as: Mas V et al. Antigenic and sequence variab
related viruses in a comprehensive dataset. Vaccine (2018), https://doi.org/10.F 3D structure, and its antigenic sites. Residues of higher variability
may thus signal sites more susceptible to changes with immune
pressure, and provide insights into the possible effectiveness of dif-
fering vaccination/prophylactic strategies.2. Methods
2.1. Search and analysis of F protein sequences
We accessed GenBank using the search term ‘‘human Respira-
tory Syncytial Virus” [txid11250], ‘‘Bovine Orthopneumovirus” [tx-
id11246] and ‘‘human Metapneumovirus” (hMPV) [txid162145]
and downloaded all the available sequencing data for these organ-
isms to the end of March 2017 (hRSV) and end of August 2017
(bRSV and hMPV). We also accessed the NIAID Virus Pathogen
Database and Analysis Resource (ViPR) through the web site at
http://www.viprbrc.org/ and downloaded all sequences available
for ‘‘Human Respiratory Syncytial Virus” to the end of March 2017.
Using a combination of custom Python scripts and the BioPy-
thon package [27] we parsed accession numbers, collection date
and country, and antigenic group (hRSV-A or B). For hRSV and
hMPV, only samples with a documented collection date and coun-
try were used in subsequent analyses, to ensure that they repre-
sented natural, rather than laboratory generated, variants (due to
small sample numbers this criterion was not applied to the bRSV
samples). Only full-length F protein sequences without indetermi-
nate nucleotides were included in the analyses. hRSV and bRSV
sequences were aligned using MUSCLE [28] in MEGA7 [29] or
MAFFT [30] to the hRSV-A A2 F protein (GenBank Accession
M74568) [31]. The hMPV F protein was aligned to the A2 reference
strain (which was used to elucidate the 3D structure of the pre-
and post-fusion F protein) with BioEdit [32], based on the recently
resolved atomic structures for these two proteins in prefusion and
postfusion conformations (see Supplementary Fig. 1).
Variability in hRSV-B, bRSV and hMPV was calculated using
amino acid sequences from the original nucleotide FASTA files.
These amino acids, once aligned to the reference A2 strain (for
bRSV, this involved truncation of the first four amino acids, which
are not shared with hRSV), were compared using customised
Python scripts; for each location we documented whether or not
a divergent amino acid existed, and the different variants. Variabil-
ity in the F protein primary structure was visualised in RStudio
with the heatmap.2 function from the gplots package [33]. As A2
is a laboratory strain of RSV, analyses were repeated using the Long
Strain, the oldest available hRSV-A F protein sequence (GenBank
Accession JX198112) [34] dating from 1956, to ensure that our
results were representative of variability with respect to a field iso-
late. In addition, within-group variability was calculated using the
oldest available field strain for both hRSV-B (CH-18537 strain, Gen-
Bank Accession JX198143, 1962) [35] and hMPV (TN/82/5–18,
GenBank Accession EU857542, 1982) [31].2.2. Modelling of antigenic sites on the prefusion and postfusion F
protein structure
3D structures of the prefusion and postfusion hRSV F glycopro-
tein were generated with PyMol [36], using PDB 4MMT [37] and
3RRR [12], respectively. Antigenic sites were defined using the
six antibody epitopes (Ø and I-V) recently described by Gilman
et al. [13]. Five out of these six antigenic sites were defined using
a single antibody binding site; for site Ø we took the aggregate
binding sites of the two antibodies used to delineate the antigenic
site. Therefore the antigenic sites were defined by taking the fin-
gerprints (5 Å pairwise distance) of the following Fab fragments:
mAb D25, site Ø, (PDB: 4JHW) [11] and 5C4, site Ø, (PDB: 5 W23)ility of the human respiratory syncytial virus F glycoprotein compared to
1016/j.vaccine.2018.09.056
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fusion F (PDB: 5 V68) [39]; mAb hRSV90, site V, bound to prefusion
F (PDB: 5TPN) [40]; mAbMotavizumab, site II, bound to prefusion F
(PDB: 4ZYP) [41]; mAb 101F, site IV, bound to a 17 mer peptide
(PDB: 2045) [12] and then modelled in prefusion F and mAb
ADI14359, site I, bound to postfusion F (PDB:6APB) [42] and again
modelled in prefusion F. With the exception of the site III-MPE8,
since quaternary structure dependency has not been described
for the binding of these antibodies to hRSVF F, to delineate each
antigenic site only the residues of a single F protomer were consid-
ered. In the case of the site III, residues at 5 Å pairwise distance
from Fab MPE8 of two F protomers were considered. The six anti-
genic sites were then mapped onto the surface structure of hRSV F
folded either in the prefusion [11,37] or the postfusion conforma-
tion [12]. The location of the six-helix bundle antigenic motif
(6HB), recognised by postfusion specific mAbs [43], was placed in
the postfusion F structure, based on reactivity of antibodies with
F protein peptides, F protein mutants and electron microscopy.
It has been reported that the most potent neutralising mAbs
bind to antigenic sites Ø, III and V, specific to (or binding preferen-
tially to) prefusion hRSV F [11,13,40,44]. Antigenic sites II and IV,
shared by the prefusion and postfusion forms of hRSV F, bind
mainly moderately neutralising antibodies. Antibodies binding to
antigenic site I have higher affinity for postfusion than for prefu-
sion F, and they are generally either non-neutralisers or weakly
neutralising. In agreement with these observations, all the antibod-
ies used in the study, except for ADI14339 (site I), are known to be
neutralising antibodies. As the most potent neutralising antibodies
bind to the prefusion form of the protein, to assess the impact of
the amino acid variability on antigenicity, sequence changes were
mapped to the 3D surface structure of hRSV F (A2 strain) folded in
its prefusion conformation.
2.3. Statistical analyses of variability within antigenic sites and other
regions
The probability of a mutation occurring inside a region defined
as an antigenic site was tested against the probability of a mutation
occurring outside these regions, for all antigenic sites and individ-
ually for each one, using a two-sided Fisher’s Exact Test imple-
mented in R [45]. The same analyses, comparing the probability
of a mutation occurring inside and outside the region, were also
repeated for different regions of the F protein: signal peptide (SP,
residues 1–23), 27 amino acid fragment (p27, residues 110–136),
fusion peptide (FP, residues 137–154), heptad repeat A (HRA, resi-
dues 157–205), heptad repeat B (HRB, residues 485–516), trans-
membrane domain (TM, residues 525–549) and cytoplasmatic
tail (CT, residues 549–574). The FP, HRA, HRB and TM, all present
in the F1 chain, are the main elements that promote membrane
fusion.
In comparisons between the A2 (or Long) hRSV F sequences and
hMPV F sequences, amino acids positions in the alignment contain-
ing gaps in hRSV, and the coordinates for p27, which is not present
in hMPV, were disregarded for the statistical analyses (see Supple-
mentary Fig. 1).
2.4. Comparison of antigenic site II in hRSV circulating strains with
laboratory mutants, bRSV and hMPV
Site II is one of the best characterised antigenic sites of hRSV F;
it was initially located in the structure of prefusion and postfusion
hRSV F by modelling the interactions of the mAb motavizumab
(Mz) with short peptides that were co-crystallised with the Mz
Fab [12,46]. Using these coordinates, we determined the amino
acid sequences found at this section of the protein, consisting ofPlease cite this article in press as: Mas V et al. Antigenic and sequence variab
related viruses in a comprehensive dataset. Vaccine (2018), https://doi.org/10.two short a-helices connected by a 6 amino acid loop (subsequent
studies have shown a larger antibody footprint, once the full F pro-
tein is used to characterise the epitope) in circulating hRSV strains,
and compared variability in these to that found in hRSV clinical
and laboratory mutants, bRSV, and hMPV. For each amino acid in
this portion of site II (residues 255–277), solvent accessible surface
area (SASA) was measured, and relative solvent accessibility for
each residue (Q) was obtained by normalising the SASA with stan-
dard values obtained from Gly-X-Gly tripeptides.
3. Results
3.1. Comparison of the F protein sequences from hRSV and bRSV
strains and from hMPV
We downloaded 16,315 hRSV, 360 bRSV and 7627 hMPV
sequences from GenBank, and 23,934 hRSV sequences from the
ViPR database. We identified 1225 records with a full hRSV F pro-
tein sequence. Samples were collected between 1956 and 2016
(median 2010), and 49.7% of samples were from the United States.
791 samples were annotated as hRSV-A, and 434 as hRSV-B. Only 6
full bRSV F protein sequences were identified from GenBank, and
289 full F protein hMPV sequences.
The 791 sequences of hRSV F from antigenic group A were com-
pared to that of reference strain A2, also belonging to antigenic
group A (Fig. 1A). In agreement with previous reports, a very lim-
ited number of sequence changes were observed [16]. Some of the
changes were found only in one or a few related strains whereas
others were present in a large number of (or most) sequences.
The changes were not evenly distributed throughout the F protein
primary structure. Instead, they accumulated preferentially in the
signal peptide (SP), in the 27 amino acid peptide between cleavage
sites I and II (p27) and in the transmembrane domain (TM). Testing
of the probability of a mutation occurring in these regions (see
Supplementary Fig. 2A) showed a statistically significant increased
odds ratio of this occurring at the SP (OR 17.89, 95% CI 5.79–73.72,
p = 1.29E09) and p27 (OR 13.36, 95% CI 5.07–41.45,
p = 1.20E09), but not for the TM. Of all these regions, HRA was
the only one that showed a significant conservation (OR 0.27,
95% CI 0.07–0.76, p = 0.007).
As expected, the number of amino acid differences with refer-
ence to the F protein of the hRSV A2 strain (antigenic group A)
increased substantially when compared with 434 sequences from
hRSV antigenic group B (Fig. 1B). Accumulation of amino acid
changes in SP, p27 and TM was now even more evident (with sta-
tistically significant increased odds ratios again for SP and p27,
Supplementary Fig. 2B), and most changes were represented in
many of the group B strains. An increased frequency of changes
can also be visualised at locations corresponding to antigenic sites
Ø (a.a. 200) and I (a.a. 380, see also Fig. 4). The hRSV F
sequences used in Fig. 1A and B come from the countries shown
in Fig. 1C. Although representing the five continents, they come
from only 19 countries, and there remain many countries from
which F protein sequence information is still missing.
Only six complete bRSV F protein sequences were available.
Nevertheless, when compared with the A2 sequence, a significant
number of sequence changes are observed, most of them shared
by the available bRSV samples (Fig. 1D). These changes accumulate
preferentially in the SP, p27 and TM regions of the F primary struc-
ture, again with significant increases in the odds ratios for SP and
p27 (Supplementary Fig. 2C). Finally, the number of amino acid
changes for hMPV F compared with the hRSV A2 strain was very
high, in agreement with only 33% approximate sequence identity
of hMPV F and hRSV F [47]. Sequence differences between hMPV
F and hRSV F were distributed throughout the entire primaryility of the human respiratory syncytial virus F glycoprotein compared to
1016/j.vaccine.2018.09.056
Fig. 1. Sequence changes in F protein primary structure. (A) 791 F protein sequences classified within antigenic group A of hRSV were aligned and compared to the sequence
of the hRSV A2 strain, taken as reference. Amino acid changes with the A2 strain are shown by vertical lines. A diagram of the F protein primary structure is shown at the top,
denoting the following structural motifs: SP, signal peptide; p27, the 27 amino acid peptide flanked by the two cleavage sites (arrowheads); FP, fusion peptide; HRA and HRB,
heptad repeats A and B, respectively; TM, transmembrane region; CT, cytoplasmic tail. (B) Representation, as in part A, of amino acid changes from 434 sequences of hRSV F
antigenic group B, compared to the A2 strain. (C) World map indicating the countries from which hRSV F sequences were obtained. Colours refer to numbers of sequences
from each country (inset). (D) Representation, as in part A, of the amino acid changes from 6 complete bRSV F sequences, compared to hRSV A2 strain and scheme of the F
protein primary structure at the top. (E) Representation of the amino acid changes from 289 sequences of the hMPV F protein, compared to hRSV A2 strain and scheme of the
hMPV F primary structure at the top. Note a gap was introduced in the hMPV F primary structure to account for the absence of p27 in this molecule.
4 V. Mas et al. / Vaccine xxx (2018) xxx–xxxstructure, although some patches of conserved sequences were dis-
cernible in the F1 and F2 chains.
Re-analyses of the same data using F Long as the reference pro-
tein showed equivalent results for groups analysed (Supplemen-
tary Fig. 3). Within-hRSV group B variability revealed similar
patterns to that shown within hRSV group A (Supplementary
Fig. 4A). Sequence changes accumulated preferentially in the SP
region and p27, although HRA is not conserved as in the case of
group A. Analyses of within hMPV F protein variability showed sig-
nificant variability only in the TM (Supplementary Fig. 4B).
3.2. Location of amino acid sequence changes in the 3D structure of the
prefusion F protein and association with antigenic sites
Fig. 2A depicts the six major antigenic sites on the surface of the
F trimer (left) and in a ribbon representation of an F2/F1 monomer
(right) both folded in the prefusion [11,37] conformation. Fig. 2B
shows the equivalent location of antigenic sites I, II and IV (shared
by prefusion and postfusion F) on postfusion F, and additionally the
site recognised by mAbs specific to the six-helix bundle (6HB)
motif characteristic of postfusion F.
To assess the impact of the amino acid variability described
above on antigenicity, these changes were mapped to the 3D sur-
face structure of hRSV F (A2 strain) folded in its prefusion confor-
mation (Figs. 3–6). Changes within hRSV group A (listed in
Supplementary Table 1) are shown in the prefusion F trimer of
the panels of Fig. 3B–G, where each of the six antigenic sites noted
previously have been individually delineated to facilitate visualisa-Please cite this article in press as: Mas V et al. Antigenic and sequence variab
related viruses in a comprehensive dataset. Vaccine (2018), https://doi.org/10.tion (coloured surface). Odds ratios with associated confidence
intervals and p-values for all the antigenic site are shown in
Fig. 3A. Overall, there was a significant decrease in the probability
of a mutation occurring within or outside an antigenic site for all 6
sites (OR 0.42, 95% CI 0.23–0.74, p = 0.001). This is in agreement
with the high level of antigenic site conservation within group A
viruses noted previously with monoclonal and polyclonal antibod-
ies [19,48,49]. Within antigenic sites, the limited sequence varia-
tion was mostly restricted to certain residues of antigenic sites Ø
and I. Sites III (OR 0.12, 95% CI 0.01–0.47, p = 1.55E5) and IV
(OR 0.21, 95% CI 0.02–0.84, p = 0.015) showed significant conserva-
tion compared to non-antigenic site regions.
The location of the sequence changes in group B hRSV F com-
pared with the A2 strain are shown in Fig. 4 and listed in Supple-
mentary Table 2. For hRSV B there was no difference in the
probability of a mutation occurring within or outside an antigenic
site for all 6 antigenic sites (OR 0.73, 95% CI 0.43–1.22, p = 0.234)
when A2 was used as the reference. Site Ø accumulated the highest
proportion of mutations of the antigenic sites, in agreement with
the group specificity of certain mAbs binding to this site [38]. Sites
V and I also showed an increased proportion of changes, compared
to other antigenic sites, although again this was not significantly
increased with respect to non-antigenic sites. As with within- hRSV
A variability, Site IV showed significant conservation compared to
non-antigenic sites (OR 0.00, 95% CI 0.00–0.48, p = 0.002). How-
ever, unlike for the hRSV A sequences, site III showed no significant
conservation, although it was, together with site II, the most con-
served antigenic site after site IV.ility of the human respiratory syncytial virus F glycoprotein compared to
1016/j.vaccine.2018.09.056
Fig. 2. Comparison of the prefusion and postfusion antigenic structures of hRSV F. The bands at the top of Fig. 2 A and B show the primary structure of the pre-cleavage F
protein with antigenic sites marked in red (site Ø), green (site I), blue (site II), purple (site III), cyan (site IV) and orange (site V). Below these to the left are surface
representation of the 3D structures of hRSV F trimer folded in its prefusion (A) [37] or postfusion conformation (B) [12]. The different antigenic sites were delineated by the
fingerprints of the Fab mAbs described in Materials and Methods, and are represented using the same colours as in the primary structure bands. The location of the six-helix
bundle antigenic motif (6HB) is based on the reactivity of antibodies with peptides, F protein mutants, and electron microscopy. Note that only certain antigenic sites are
shared by prefusion and postfusion hRSV F. To the lower right of A and B a single RSV F protomer in ribbon representation of the prefusion (A) and postfusion (B) conformation
is shown, with the epitopes marked with the same colours as the bands and surface representations. (For interpretation of the references to color in this figure legend, the
reader is referred to the web version of this article.)
V. Mas et al. / Vaccine xxx (2018) xxx–xxx 5The changes of the A2 strain compared with the limited num-
ber of bRSV F sequences are shown in Fig. 5 and listed in Supple-
mentary Table 3. When compared with the amino acid differences
between hRSV F of group B strains and the A2 strain, it seems
that bRSV F may show even fewer differences, but this is likely
a consequence of the small number of bRSV F sequences avail-
able. However, their distribution on the prefusion F structure is
similar to that for RSV A and B, with antigenic site Ø accumulat-
ing the most differences (OR 2.30, 95% CI 0.94–5.41, p = 0.06) and
sites III and IV showing relative conservation. Overall, the similar-
ities between bRSV and hRSV are in agreement with the high
level of cross-reactivity between bRSV F and hRSV F observed
with murine and bovine mAbs [50] as well as with certain human
mAbs [44].
Finally, the number of sequence changes between hRSV F A2
strain and hMPV F sequences were very high, and distributed
throughout most of the prefusion F surface, including residues in
the six antigenic sites (Fig. 6 and Supplementary Table 4); as with
hRSV B and bRSV there was no difference in the probability of a
mutation occurring within or outside an antigenic site region (OR
0.98, 95% CI 0.64–1.50, p = 0.918). However, some patches of con-
served residues were noted in antigenic sites III, which showed rel-
ative conservation compared to other non-antigenic sites (OR 0.44,
95% CI 0.23–0.83, p = 0.007) which may account for the observed
cross-reactivity between hRSV F and hMPV F with a site III specific
mAb (MPE8) [44]. None of the mutations which have been shown
to reduce MPE8 binding (R49D,T50A L305R, G307R and D310A)
[44] were identified in either the hRSV or hMPV strains. Although
site IV did not show significant conservation compared to non-Please cite this article in press as: Mas V et al. Antigenic and sequence variab
related viruses in a comprehensive dataset. Vaccine (2018), https://doi.org/10.antigenic sites, it had the lowest proportion of changes after site
III, which may again explain the cross-reactivity of two mAbs bind-
ing to this site for hRSV and hMPV, one of which is 101F, used to
define this site in our study [51,52]. The two most variable anti-
genic sites when comparing the A2 reference with the hMPV F
sequences were site II and to a more minor extent site Ø. It is pos-
sible that the variability seen in site II, not observed in the circulat-
ing hRSV or bRSV sequences, indicates the potential for this region
of the protein to incorporate amino acid changes, some of which
are also observed in the hRSV site II escape mutants discussed
below.
As in the case of F regions previously commented, re-analyses of
variability within the antigenic sites using F Long as the reference
protein showed equivalent results for all groups and species (Sup-
plementary Fig. 3). In addition, within hRSV B analyses showed
that, as when A2 or F Long was used as a reference, (i) there was
no difference in the probability of a mutation occurring within or
outside an antigenic site for all 6 antigenic sites, (ii) site Ø, V and
I accumulated the highest proportion of mutations of the antigenic
sites, and (iii) site IV again showed significant conservation com-
pared to non-antigenic sites (Supplementary Fig. 4A). Finally, anal-
ysis of within hMPV variability showed that the antigenic site with
the highest variability was site V (OR 4.7, 95% CI 1.62–13.45,
p = 0.002) rather than site Ø (Supplementary Fig. 4B). This observa-
tion is in agreement with the hypothesis that site Ø accessibility to
antibodies is limited due to a dense glycan shield at the apex of the
hMPV F protein [53], so that immune pressure resulting in amino
acid variability may be reflected to a greater extent in other anti-
genic sites, such as site V or site II.ility of the human respiratory syncytial virus F glycoprotein compared to
1016/j.vaccine.2018.09.056
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Site II includes mainly two short a-helices connected by a 6
amino acid loop. This structural motif is exposed at the surface ofPlease cite this article in press as: Mas V et al. Antigenic and sequence variab
related viruses in a comprehensive dataset. Vaccine (2018), https://doi.org/10.both prefusion and postfusion F (Fig. 2), explaining the capacity
of site II specific mAbs to bind to both forms of hRSV F. A number
of escape mutants have been isolated by different groups with
mAbs that bind to antigenic site II. Most laboratory mutants wereility of the human respiratory syncytial virus F glycoprotein compared to
1016/j.vaccine.2018.09.056
V. Mas et al. / Vaccine xxx (2018) xxx–xxx 7selected with mAbs of murine origin [20,21,54] but also with
Nanobodies [55] or with bovine mAbs [18]. Some of these muta-
tions, specifically those at residues 272 and 275, have been also
found in sequences of hRSV F obtained from nasopharyngeal secre-
tions of children infected with hRSV that were treated prophylac-
tically with either palivizumab (Pz) or Mz [25,26]. In some cases
the same mutations were identified in both laboratory mutants
and strains found in patients (eg K272M and S275F). All these
escape mutants show amino acid changes preferentially at the sur-
face of the prefusion-F (cyan shading in Fig. 7A and E), that allow
the avoidance of antibody /nanobody binding. Of note, studies of
in vitro escape mutants and of recombinant viruses containing site
II mutations isolated in clinical samples have shown that the fit-
ness of these mutants is impaired in comparison with the wild-
type RSV in the absence of Pz or Mz [26].
Within the hRSV A group viruses, only two residues (255 and
276) are mutated within antigenic site II; none of the exact
amino acid substitutions are shared with an escape mutant.
The sequences from the hRSV B strains show full conservation
within this portion of the antigenic site (Fig. 7), except for resi-
due 276, that was also found to be mutated in laboratory strains
which acquired resistance to mAbs. Again, in these cases the
amino acid variant found in circulating B strains (Ser) differs
from that found in the laboratory escape mutants (Tyr). This high
degree of conservation of antigenic site II between hRSV group A
and B correlates with the high degree of cross-reactivity observed
with site II specific mAbs. Similarly, the antigenic site II of bRSV F
has only two amino acid changes when compared to hRSV F. One
of these (L260I) is not surface exposed, and the other (N276S) is
the same as that seen in some group A and B viruses (Fig. 7). This
result correlates with the finding that the majority of mAbs
raised against bRSV F, including at least 12–14 specific for anti-
genic site II, cross-react with hRSV F [50,56]. However, a higher
number of sites of amino acid changes in hMPV F antigenic site
II (12 out of 23 residues), including some found in escape
mutants (Fig. 7), likely preclude site II cross-reactivity between
hRSV F and hMPV F.
In summary, single amino acid changes, as seen in escape
mutants, can have a high impact on antibody binding. The limited
variability found in site II across the sequences analysed suggest
that site II is not currently under strong enough selective pressure
during natural infections to overcome the reduced overall fitness
caused by mutations within site II. However, the high variability
of this site seen in the circulating hMPV sequences (with a signif-
icantly increased probability of mutation), where some of the
amino acid variants observed are shared with documented hRSV
escape mutants, indicates the potential for this region of the pro-
tein to incorporate amino acid changes in a scenario where strong
enough selective pressure (eg. in the form of widespread mAb
administration) is present.4. Discussion
In the present study, in order to provide insights into the possi-
ble effectiveness of differing vaccination/immunisation strategies,Fig. 3. Location of amino acid differences between A2 and group A strains on the struc
mutation occurring inside or outside an antigenic site. For each antigenic site and for all a
a 95% confidence interval. Significantly (p < 0.05) increased or reduced values are display
(B–G) The surface of the prefusion F trimer is shown in each panel with the indicated anti
acids are colour based on the number of changes in a given residue: no variants in oran
included in each antigenic site are denoted in the different panels. When the number of a
in a box, as for instance in antigenic site I (panel G). The changes are listed in Supple
intensities of grey and black, where white indicates sequence conservation. (For interpret
version of this article.)
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related viruses in a comprehensive dataset. Vaccine (2018), https://doi.org/10.we have analysed the variability of RSV F in circulating viruses
focusing on F regions including the six major known antigenic sites
(Ø and I-V). However, we cannot exclude the possibility that addi-
tional sites may also be involved in antibody responses to RSV F;
the antigenic sites for a proportion of anti-hRSV F protein human
antibodies isolated from adults and infants remain unidentified
[13,42]. Although F regions such as the HRB could be novel, as
yet unrecognised, antigenic sites, another alternative is that since
all the antibodies used to determine the antigenic sites were iso-
lated using soluble trimeric forms of cleaved F proteins, additional
F regions not present in these trimeric forms could also represent
relevant antigenic sites for hRSV. Supporting this, the high degree
of variability that we observed in p27 in hRSV and bRSV suggests
that this region may also constitute an antigenic target that could
be under immune pressure in natural infections, possibly in speci-
fic age groups: a study found that antibodies to the p27 region
were found predominantly in children under the age of 2 [57].
We also found high variability in the SP sequences in hRSV and
bRSV. Recent work in HIV has shown that the signal peptide can
affect the glycan profile of the adjacent gp120 protein, and thus
its immunogenicity [58]; it is possible that a similar process may
take place in hRSV.Structural implications of F protein variability
The results of previous sections raise important questions about
the F glycoprotein from a structural and biological point of view.
For instance, why are antigenic sites Ø and V ones that accumulate
a high number of amino acid differences between group A and
group B hRSV strains? Both sites are located at the apex of the pre-
fusion F protein which includes a series of short a-helices that are
rearranged in a long a-helix when the F protein adopts the postfu-
sion conformation (Fig. 2A and B). It may be argued then that the
region of prefusion F where antigenic sites Ø and V are placed
requires a degree of structural flexibility reflected in a less
restricted partial amino acid sequence.
Conversely, the question arises about the relative conservation
of antigenic sites III and IV when group A and B strains of hRSV
and bRSV are compared. Secondary structural elements of site III
and IV are shared between prefusion and postfusion F. However,
in the case of site III, they adopt a different spatial arrangement
in postfusion F, which explains the higher affinity of site III anti-
bodies to pre- rather than to postfusion F [39]; for site IV antibod-
ies, the affinity remains the same for the two F protein
conformations. Site III and site IV are the main regions constituting
the inter-protomeric cavity present approximately midway
between the apex and tail (C-terminus F1) of the prefusion trimer
(Fig. 2A). In addition, site IV is the site around which the short a-
helix and the sole parallel strand of the C-terminus F1 unravel
and rotate to form the 6-HB motif (Fig. 2B). Thus, antigenic site
III (which is also significantly conserved when compared to the
hMPV sequences) and IV may be restricted in incorporating
sequence changes that would disrupt their essential role in the glo-
bal structure of the protein, and in the transition from prefusion to
postfusion F.ture of prefusion hRSV F. (A) Fisher’s exact tests are shown for the probability of a
ntigenic sites grouped together (‘‘All sites”), data are presented as an odds ratio with
ed in blue and orange, respectively, with non-significant odds ratios shown in black.
genic site delineated in color as identified in Fig. 2. Within each antigenic the amino
ge, 1 variant in cyan, 2 variants in blue and 3 variants in red. Amino acid changes
mino acid changes prevented showing them individually, the changes were included
mentary Table S1. Amino acid outside the antigenic site are shown in increasing
ation of the references to color in this figure legend, the reader is referred to the web
ility of the human respiratory syncytial virus F glycoprotein compared to
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Fig. 4. Location of amino acid differences between A2 and group B strains on the structure of prefusion hRSV F. Structures and changes are shown as in Fig. 3. The changes are
listed in Supplementary Table S2.
8 V. Mas et al. / Vaccine xxx (2018) xxx–xxxThe higher or lower degree of structural restriction in different
elements of the F protein may also have immunological conse-
quences, such as the group-dependent neutralisation of hRSV by
certain antibodies specific to antigenic site Ø [38].Please cite this article in press as: Mas V et al. Antigenic and sequence variab
related viruses in a comprehensive dataset. Vaccine (2018), https://doi.org/10.Immunological implications of F protein variability
Most viral immunisations used in humans take the form of live
attenuated vaccines (measles, mumps, rubella, varicella, rotavirus,ility of the human respiratory syncytial virus F glycoprotein compared to
1016/j.vaccine.2018.09.056
Fig. 5. Location of amino acid differences between A2 and bRSV strains on the structure of prefusion hRSV F. Structures and changes are shown as in Fig. 3. The changes are
listed in Supplementary Table S3.
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Fig. 6. Location of amino acid differences between A2 and hMPV strains on the structure of prefusion hRSV F. Structures and changes are shown as in Fig. 3. The changes are
listed in Supplementary Table S4.
10 V. Mas et al. / Vaccine xxx (2018) xxx–xxxpolio – oral Sabin, yellow fever, influenza, dengue) or killed virus
(influenza, polio, hepatitis A, rabies), and thus stimulate both poly-
clonal humoral responses and T cell responses to a wide variety ofPlease cite this article in press as: Mas V et al. Antigenic and sequence variab
related viruses in a comprehensive dataset. Vaccine (2018), https://doi.org/10.viral proteins. A key question is how viral genetic variability may
affect vaccine efficacy. For influenza, antigenic drift, particularly
in the haemagglutinin protein, certainly affects the efficacy ofility of the human respiratory syncytial virus F glycoprotein compared to
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Fig. 7. Amino acid changes in antigenic site II. (A) The amino acids included in antigenic site II of hRSV F, A2 strain, are shown in the header of the table with a single letter
code. Solvent accessible surface area (SASA) and relative solvent accessibility (Q) values for each residue are shown below this. Cyan indicates highly exposed residues
(Q > 0.5) at the prefusion F surface. The amino acid changes selected in escape mutants were reported in the indicated references. The last four lines show the amino acid
changes seen when comparing the A2 strain other hRSV group A strain, hRSV group B, bRSV and hMPV F, respectively. (B) Side view of prefusion hRSV F. One protomer is
shown as ribbons colored in green with antigenic site II colored in yellow. Molecular surfaces are shown for the other two protomers, colored grey and dark grey. (C)
Magnified antigenic site II in yellow. (D) Further magnification with side chains of residues shown as sticks and highly exposed residues labeled. (E) Fraction of solvent
accessible surface area for the antigenic site II colored on a per-residue basis: magenta (0%, ‘‘buried”) to cyan (100%, ‘‘accessible”). (For interpretation of the references to color
in this figure legend, the reader is referred to the web version of this article.)
V. Mas et al. / Vaccine xxx (2018) xxx–xxx 11seasonal vaccines, requiring regular updating of vaccine strains in
order to match circulating strains. However, whether these vacci-
nations themselves exert selective pressure on circulating viruses
remains unclear [59–61].
However, there are examples where single viral proteins, as
opposed to the whole virus, are used as sole components in immu-
nisation campaigns, and these vaccines may be more prone to fail-
ure to protect against infection by specific viral subtypes, or to the
development of vaccine resistant strains. For example, the human
papilloma virus (HPV) vaccine consists of a recombinant viral L1
protein which spontaneously self assembles into a virus like pro-
tein, or VLP, and which is used to elicit an antibody response. VLPs
are known to stimulate a polyclonal immune response, but in this
case the response to HPV L1 protein is subtype specific. Thus, the
current vaccines which include genotypes 6, 11, 16 and 18 do
not provide protection against subtypes such as 52 and 58, which
are more common in Asian countries [62]. Similarly, the current
hepatitis B vaccine (HBV) takes the form of recombinant hepatitis
B surface antigen (HbsAg) adsorbed onto an adjuvant; the majority
of antibodies raised by this vaccine are directed against epitopesPlease cite this article in press as: Mas V et al. Antigenic and sequence variab
related viruses in a comprehensive dataset. Vaccine (2018), https://doi.org/10.located in a single hydrophilic stretch of twenty five amino acids
in the middle of the molecule [63]. In the case of the Hepatitis B
vaccine, escape mutants with single amino acid changes in the rel-
evant antigen have been identified which evade the immune
response in vaccinated individuals [63]. Thus, the HPV and HBV
vaccines are two examples in which antibody responses, although
polyclonal, only recognise a restricted range of epitopes, deter-
mined by the protein used to manufacture the vaccine.
Could hRSV vaccines follow the aforementioned examples of
HPV and HBV? The F protein has at least six antigenic sites; the
study looking at human antibody responses to the F protein used
to characterise antigenic sites Ø to V showed that all the individu-
als mounted responses to all the antigenic sites [13], and thus none
is fully dominant over the others. Therefore, it might be expected
that anti-F antibodies elicited by an hRSV vaccine would bind sev-
eral epitopes, thus reducing the probability of selecting escape
mutants that will require the simultaneous incorporation of sev-
eral independent point mutations. However, it is important to con-
sider that the target population may influence the antibody
specificities of the vaccine. Goodwin et al. [42] have recentlyility of the human respiratory syncytial virus F glycoprotein compared to
1016/j.vaccine.2018.09.056
12 V. Mas et al. / Vaccine xxx (2018) xxx–xxxreported a narrower range of antibody specificities produced by B-
lymphocytes obtained from very young children after an hRSV
infection than the B-lymphocytes obtained from adults; neutralis-
ing responses in adults predominantly targeted site Ø, whilst those
in children targeted site III. A thorough analysis of the antibodies
induced by future hRSV vaccines will provide information about
the necessity of incorporating F proteins from more than one anti-
genic group if the antibody specificities are skewed to group speci-
fic epitopes, such as some of those present in antigenic site Ø. As
alluded to previously, type specific (ie hRSV A or B) site Ø antibod-
ies [38] have been documented, laying open the possibility of
replacement of certain strains by others if hRSV vaccines were to
predominantly induce antibodies to sites containing A or B group
specific epitopes.
The argument of restricted antibody repertoire in hRSV vaccines
becomes even more relevant in the case of prophylaxis with mAbs,
which by definition recognise a single epitope. So far the only mAb
used clinically is palivizumab (Pz) which recognizes the site II anti-
genic site of hRSV F. Pz is recommended for children at high risk of
having a severe infection (born preterm or with congenital heart or
lung disease) [64] and therefore has limited use. Nonetheless, there
are indications of escape mutant viruses with amino acid changes
in antigenic site II in a minority of clinical specimens from children
treated with Pz but nevertheless infected by hRSV [25,26], as
shown in Fig. 7. A potentially relevant counterpart for RSV is the
case of measles. Here, there is little evidence of antigenic drift in
circulating populations in response to the widespread administra-
tion of live attenuated vaccines, presumably due to the polyclonal
response elicited by the whole virus. However, similarly to RSV,
escape mutants have been documented in response to monoclonal
antibodies in laboratory settings [65]. A clinical example for the
selective pressure of neutralising antibodies exists for HIV, where
25% patients treated with the monoclonal antibody ibalizumab
showed reduced susceptibility to the agent with prolonged treat-
ment, associated with mutations in the antibody binding site
[66]. Taken together, these examples suggest that an immunisation
campaign based on the widespread administration of mAbs, rather
than vaccines based on a single or multiple RSV proteins, are more
likely to lead to selection pressure favouring the emergence of
mutants, due to the absence of a polyclonal response to infection.
The study which identified mAb resistant measles strains did
not attempt to measure the relative fitness of the mutant strains
compared to wildtype. However, for RSV, one of the studies which
identified escape mutants in a clinical population [26] found these
to have reduced fitness compared to circulating strains. These vari-
ants are probably less likely to circulate in the community because
of a growth disadvantage. However, as evidenced by the site II vari-
ability observed between hRSV and hMPV sequences (Fig. 6), the
possibility that an extended passive immunisation programme
might lead to the development of alternative variants with
improved fitness that could circulate in the community cannot
be discarded. In this scenario, the likelihood of an RSV strain
emerging in response to the widespread administration of a mon-
oclonal antibody is likely to be determined by the balance between
benefits provided to the virus by particular mutations preventing
antibody neutralisation, and the consequences to viral fitness of
that mutation. This balance, as suggested by the varying propor-
tions of mutations seen in different antigenic sites in our study,
is likely to be antigenic site specific: a study examining site Ø
escape mutants found no difference in fitness for the mutants
[22] compared to circulating strains.
In this respect, the genetic stability of certain antigenic sites,
such as sites III and IV, which we find to be conserved to different
extents in hRSV A, hRSV B, bRSV and hMPV, may be an advantage
in the selection of future mAbs for prophylactic use. In vitro escape
mutants have in fact been isolated for site IV antibodies, but infor-Please cite this article in press as: Mas V et al. Antigenic and sequence variab
related viruses in a comprehensive dataset. Vaccine (2018), https://doi.org/10.mation on the fitness of these variants is not available [19]. For site
III, the attempt to isolate in vitro escape mutants against MPE8
failed [44], and, in addition, the unique site III escape mutant iso-
lated using a nanobody showed strongly impaired fitness, where
viral growth was not observed in the absence of the nanobody
[23]. These data support the limited potential of this region to
mutate, as reflected in the limited sequence variability of the anti-
genic site when comparing hRSV and related species, and highlight
its potential use as a target for immunisation programs.5. Conclusion
If vaccination or other prophylactic measures take approaches
that could place selective pressure on particular F protein epitopes,
our analyses show that a considerable degree of amino acid vari-
ability is tolerated in hRSV F and closely related viruses. It would
therefore seem prudent to coordinate efforts for prospective sam-
ple collection that might identify potential evolutionary changes in
the virus driven by these immunisation programs.ICMJE statement
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